Mystery 'major pharma' lender negotiating license to Medicago vaccine tech
This article was originally published in Scrip
Executive Summary
Plant-based vaccine developer Medicago announced a non-dilutive loan agreement for Can$15 million with an unnamed "major pharmaceutical company" that is negotiating a license for the Canadian firm's vaccine technology.